S'abonner

Do Cinnamon Supplements Have a Role in Glycemic Control in Type 2 Diabetes? A Narrative Review - 25/10/16

Doi : 10.1016/j.jand.2016.07.015 
Rebecca B. Costello, PhD , Johanna T. Dwyer, DSc, RD, Leila Saldanha, PhD, RD, Regan L. Bailey, PhD, MPH, RD, Joyce Merkel, MS, RD, Edwina Wambogo, MS, MPH, RD, LDN

Address correspondence to: Rebecca B. Costello, PhD, Office of Dietary Supplements, National Institutes of Health, 6100 Executive Blvd, Suite 3B01, Bethesda, MD 20892.Office of Dietary SupplementsNational Institutes of Health6100 Executive Blvd, Suite 3B01BethesdaMD 20892

Abstract

Cinnamon (Cinnamomum sp) has been suggested to help patients with type 2 diabetes mellitus (T2DM) achieve better glycemic control, although conclusions from meta-analyses are mixed. To evaluate whether the use of cinnamon dietary supplements by adults with T2DM had clinically meaningful effects on glycemic control, as measured by changes in fasting plasma glucose (FPG) or hemoglobin A1c (HbA1c), a comprehensive PubMed literature search was performed. Eleven randomized controlled trials were identified that met our inclusion criteria that enrolled 694 adults with T2DM receiving hypoglycemic medications or not. In 10 of the studies, participants continued to take their hypoglycemic medications during the cinnamon intervention period. Studies ranged from 4 to 16 weeks in duration; seven studies were double-blind. Cinnamon doses ranged from 120 to 6,000 mg/day. The species of cinnamon used varied: seven used Cinnamomum cassia or Cinnamomum aromaticum, one used Cinnamomum zeylanicum, and three did not disclose the species. Because of the heterogeneity of the studies, a meta-analysis was not conducted. All 11 of the studies reported some reductions in FPG during the cinnamon intervention, and of the studies measuring HbA1c very modest decreases were also apparent with cinnamon, whereas changes in the placebo groups were minimal. However, only four studies achieved the American Diabetes Association treatment goals (FPG <7.2 mmol/L [130 mg/dL] and/or HbAlc <7.0). We conclude that cinnamon supplements added to standard hypoglycemic medications and other lifestyle therapies had modest effects on FPG and HbA1c. Until larger and more rigorous studies are available, registered dietitian nutritionists and other health care professionals should recommend that patients continue to follow existing recommendations of authoritative bodies for diet, lifestyle changes, and hypoglycemic drugs.

Le texte complet de cet article est disponible en PDF.

Keywords : Cinnamon, Fasting plasma glucose, Hemoglobin A1c, Type 2 diabetes mellitus


Plan


 STATEMENT OF POTENTIAL CONFLICT OF INTEREST Johanna T. Dwyer holds stock in and currently serves on the Scientific Advisory Board of McCormick Inc. No potential conflict of interest was reported by the other authors.
 FUNDING/SUPPORT This work was supported by the Office of Dietary Supplements of the National Institutes of Health, Department of Health and Human Services. Partial support was also provided by the US Department of Agriculture, Agricultural Research Service, under agreement no. 58-1950-0-014.


© 2016  Academy of Nutrition and Dietetics. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 116 - N° 11

P. 1794-1802 - novembre 2016 Retour au numéro
Article précédent Article précédent
  • Effects of Bite Count Feedback from a Wearable Device and Goal Setting on Consumption in Young Adults
  • Phillip W. Jasper, Melva T. James, Adam W. Hoover, Eric R. Muth
| Article suivant Article suivant
  • “Great Job Cleaning Your Plate Today!” Determinants of Child-Care Providers’ Use of Controlling Feeding Practices: An Exploratory Examination
  • Dipti A. Dev, Brent A. McBride, Katherine E. Speirs, Kimberly A. Blitch, Natalie A. Williams

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.